华东医药三项GLP-1药物重磅亮相2025ADA大会

Group 1 - Company announced research results of three innovative GLP-1 drugs at the 85th American Diabetes Association (ADA) Scientific Sessions in 2025 [1] - The self-developed GLP-1/GIP dual-target long-acting agonist HDM1005 was selected for an oral presentation at the conference [1] - HDM1005 is undergoing Phase II clinical trials for weight management and is expected to enter Phase III trials in Q4 2025 [1] Group 2 - HDM1002 is a new oral non-peptide GLP-1 receptor agonist, with a Phase I clinical study focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics in overweight or obese subjects [2] - The Phase III clinical study for weight management indication of HDM1002 has completed the first subject enrollment in April 2025 [2] - The submission for marketing approval of the semaglutide injection for diabetes indication was accepted in March 2025 [2] Group 3 - Company ranked 41st in the "2025 Global Pharmaceutical Companies Top 50" list published by Pharmaceutical Executive magazine, marking a historic high with six Chinese companies on the list [3] - This ranking reflects the company's enhanced comprehensive competitiveness and international recognition [3]